2026 Price Guide,GLP

Glucagon-like peptide 1 (GLP-1) (7-36) amide human is a fascinating and critically important peptide hormone with significant physiological roles, particularly in glucose metabolism. As a prominent incretin hormone, it plays a vital part in regulating insulin secretion and influencing various metabolic processes within the human body. This article delves into the scientific understanding of GLP-1 (7-36) amide human, drawing upon extensive research and offering verifiable details about its function, production, and therapeutic potential.

The Nature and Origin of GLP-1 (7-36) Amide Human

Glucagon-like peptide-1 (7-36) amide (GLP-1) is a 36 amino acid polypeptide that is a biologically active form of GLP-1. It is produced through the post-translational processing of proglucagon, a larger precursor protein. This processing occurs primarily in the intestinal L-cells, which are specialized endocrine cells found in the lining of the small and large intestines. Upon nutrient consumption, these L-cells release GLP-1 (7-36) amide, along with other peptides, into the bloodstream. In humans, the amidated form, GLP-1 (7-36) amide, represents the predominant and biologically active form, with over 80% of secreted GLP-1 undergoing amidation, unlike in some other species where the non-amidated form, GLP-1 (7-37), is more prevalent.

This peptide is a member of the glucagon family and shares structural similarities with glucagon. Its sequence is identical in human, rat, and mouse, highlighting its conserved biological importance across species. The molecular formula for Glucagon-Like Peptide 1 (7-36) Amide is C149H226N44O45, with a molecular weight of approximately 3297.67 Da. The CAS Number associated with this specific compound is 107444-51-9. Researchers often refer to it by synonyms such as GLP-1(7-36)amide or Glucagon-Like Peptide (GLP) I Amide Fragment 7-36 human.

Physiological Functions and Mechanisms of Action

The primary role of GLP-1 (7-36) amide human is as an incretin hormone. Incretins are gut hormones released in response to food intake that enhance insulin secretion from pancreatic beta cells. This action is glucose-dependent, meaning that GLP-1 (7-36) amide stimulates insulin release only when blood glucose levels are elevated. This crucial mechanism helps to prevent hypoglycemia (low blood sugar).

Beyond its insulinotropic effects, GLP-1 (7-36) amide exerts several other beneficial metabolic actions:

* Suppression of Glucagon Secretion: It reduces the secretion of glucagon, a hormone that raises blood glucose levels by stimulating the liver to release stored glucose. By lowering glucagon, GLP-1 (7-36) amide further contributes to glycemic control.

* Delayed Gastric Emptying: GLP-1 (7-36) amide slows down the rate at which food leaves the stomach. This delay helps to reduce the post-meal surge in blood glucose and promotes a feeling of fullness, potentially aiding in appetite regulation. Research has indicated that GLP-1 is a candidate physiological inhibitory regulator of fundus motility.

* Neurotransmitter Modulation: Evidence suggests that GLP-1 (7-36) amide derived from gut or brain sources can induce effects on the release of neurotransmitters from selective brain nuclei, hinting at a broader role in central nervous system regulation.

* Potential Anabolic Effects: Some studies suggest that GLP-1 (7-36) amide may exert anabolic effects, particularly on whole-body protein metabolism.

Therapeutic Implications and Research

The remarkable physiological properties of glucagon-like peptide 1 (7-36) amide human have positioned it as a significant target for therapeutic interventions, particularly in the management of type 2 diabetes mellitus. The ability of GLP-1 (7-36) amide to improve glycemic control by enhancing insulin secretion in response to elevated blood glucose levels, coupled with its glucagon-lowering effects, makes it a valuable therapeutic agent.

The short half-life of native GLP-1 (7-36) amide in circulation, due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), has spurred the development of GLP-1 receptor agonists and DPP-4 inhibitors. These pharmaceutical advancements aim to mimic or prolong the action of endogenous GLP-1. For instance, lixisenatide has been shown in vitro to bind to the human GLP-1 receptor (GLP-1R) with greater affinity than native